SCHEMBL4124888

SCHEMBL4124888

CC(Cc1nc2ccccc2[nH]1)C(F)(F)F

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DDAH1 O94760 1/20 0.56
MAPK1 P28482 2/20 0.53
ALPL P05186 2/20 0.53
POLB P06746 1/20 0.51
PKM P14618 1/20 0.50
CYP2D6 P10635 2/20 0.49
CYP2C9 P11712 2/20 0.49
CYP2C19 P33261 2/20 0.49
CYP3A4 P08684 2/20 0.49
KMT2A Q03164 2/20 0.49
MEN1 O00255 1/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
L3MBTL1 Q9Y468 1/20 0.49
GAA P10253 1/20 0.49
LMNA P02545 1/20 0.48
ALPI P09923 1/20 0.48
MAPT P10636 1/20 0.48
ALPG P10696 1/20 0.48
HTT P42858 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4113303 0.82 DDAH1 (0.65) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL133478 0.79 DDAH1 (0.61) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL2680248 0.79 CYP3A4 (0.64) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL13050694 0.79 CYP3A4 (0.64) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL8025715 0.79 DDAH1 (0.61) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL30207649 0.79 DDAH1 (0.61) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL20646170 0.79 DDAH1 (0.61) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL20677814 0.78 DDAH1 (0.63) DDAH1MAPK1ALPLPOLBPKM
SCHEMBL9854258 0.78 PDE9A (0.38) DDAH1MAPK1ALPLPKMTP53
SCHEMBL4106172 0.78 DDAH1 (0.64) DDAH1MAPK1ALPLPOLBPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2007117778-A9 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS INC (US) 2009-05-22 WO disclosed
EP-1986747-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS Kalypsys, Inc. (US) 2008-11-05 EP disclosed
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2008-06-12 US disclosed
WO-2007117778-A2 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS KALYPSYS, INC. (US) 2007-10-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080139558-A1 QUINOLONES USEFUL AS INDUCIBLE NITRIC OXIDE SYNTHASE INHIBITORS NOS2, NOS1, NQO2 DDAH1 274/4885MAPK1 1816/4885ALPL 2931/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.